1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Active Pharmaceutical Ingredient Market by type, Type of Synthesis, Type of Manufacturer, Therapy - Global Forecast to 2020

The Active Pharmaceutical Ingredients market is categorized on the basis of type, type of manufacturer, type of synthesis, therapeutic area and region. Factors such as increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets for biosimilars and increasing scope for Highly potent active ingredients are driving market growth. On the other hand, stringent regulatory guidelines and global economic recession may restrict market growth in the forecast period.

North America accounts for the highest share of the global APIs market. The overall technological advancements in this region coupled with factors like increase in lifestyle and age related disorders in this region, the increase in demand for specialty biological and specialty drugs and increasing government focus on generics following the implementation of the Patient Protection and Affordable Care Act is driving the growth of this market.

Apart from the comprehensive geographical analysis, product analysis, and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, and change in strategic approach; R&D investments; and levels of output in order to remain successful.

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of top players in the APIs market. The report analyzes the APIs and HPAPIs market by type, type of synthesis, type of manufacturer, therapeutic area and region.
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the APIs market
- Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of the leading players in APIs market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for APIs across geographies
- Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the APIs market

Table Of Contents

Active Pharmaceutical Ingredient Market by type, Type of Synthesis, Type of Manufacturer, Therapy - Global Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 LIMITATIONS 21
1.5 CURRENCY 21
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY RESEARCH 23
2.1.1.1 Key data from secondary sources 24
2.1.2 PRIMARY RESEARCH 24
2.1.2.1 Key data from primary sources 25
2.1.2.2 Key industry insights 26
2.1.2.3 Breakdown of primaries 26
2.2 MARKET SIZE ESTIMATION 27
2.2.1 BOTTOM-UP APPROACH 27
2.2.2 TOP DOWN APPROACH 28
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS 30
2.4.1 ASSUMPTIONS 30
2.4.2 LIMITATIONS 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 40
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 40
4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA 41
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS 42
4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 43
4.5 GEOGRAPHIC SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 44
4.6 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 45
4.7 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 46
4.8 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 47
4.9 GEOGRAPHIC SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 50
5.2 MARKET SEGMENTATION 50
5.2.1 BY TYPE 50
5.2.2 MARKET SEGMENTATION, BY TYPE OF SYNTHESIS 51
5.2.3 MARKET SEGMENTATION, BY TYPE OF MANUFACTURER 51
5.2.4 MARKET SEGMENTATION, BY THERAPEUTIC AREA 52
5.2.5 MARKET SEGMENTATION, BY REGION 53
5.3 MARKET DYNAMICS 54
5.3.1 DRIVERS 55
5.3.1.1 Increasing incidence of lifestyle and age-related diseases 55
5.3.1.2 Rising cancer prevalence across the globe 55
5.3.1.3 Technological advancements in API manufacturing 55
5.3.2 RESTRAINTS 56
5.3.2.1 Stringent regulatory requirements 56
5.3.2.2 Economic recession 56
5.3.3 OPPORTUNITIES 57
5.3.3.1 Emerging biosimilars market 57
5.3.3.2 Increasing scope for highly potent active pharmaceutical ingredients 57
5.3.4 CHALLENGES 57
5.3.4.1 Product differentiation - A major concern for API manufacturers 57
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SYNTHESIS 58
6.1.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 59
6.1.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE 62
6.1.2.1 Innovative Synthetic APIs 63
6.1.2.2 Generic Synthetic APIs 63
6.1.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 63
6.1.3.1 Biotech APIs Market, by Product 68
6.1.3.1.1 Monoclonal Antibodies 69
6.1.3.1.2 Recombinant Proteins 70
6.1.3.1.3 Vaccines 70
6.1.3.2 Biotech APIs Market, by Type 70
6.1.3.2.1 Innovative Biotech APIs 71
6.1.3.2.2 Biogenerics/Biosimilars 71

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 73
7.1 INTRODUCTION 74
7.2 CAPTIVE API MANUFACTURERS 75
7.3 MERCHANT API MANUFACTURERS 78
7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE 81
7.3.1.1 Innovative APIs 82
7.3.1.2 Generic APIs 82
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 83
8.1 INTRODUCTION 84
8.2 INNOVATIVE APIS SEGMENT 85
8.3 GENERIC APIS SEGMENT 87
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA 89
9.1 ONCOLOGY 91
9.2 DIABETES 92
9.3 CARDIOVASCULAR DISEASE 93
9.4 CNS AND NEUROLOGICAL DISORDERS 94
9.5 ORTHOPEDIC DISORDERS 95
9.6 NEPHROLOGY 95
9.7 OPHTHALMOLOGY 95
9.8 PULMONOLOGY 96
9.9 GASTROINTESTINAL DISORDERS 96
9.10 ENDOCRINOLOGY 96
10 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 97
10.1 INTRODUCTION 98
10.1.1 HPAPI CLASSIFICATION 100
10.1.2 OVERVIEW: HPAPI GLOBAL MARKET 101
10.1.3 MANUFACTURING CAPABILITIES 102
10.1.3.1 Handling requirements 102
10.1.3.2 Personnel considerations 102
10.1.3.3 Plant and equipment 102
10.1.3.4 Technology 103
10.2 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 103
10.2.1 HPAPI MARKET, BY TYPE 103
10.2.1.1 INNOVATIVE HPAPI 104
10.2.1.2 GENERIC HPAPI 104

10.3 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 106
10.3.1.1 CAPTIVE HPAPI SECTOR 107
10.3.1.2 MERCHANT HPAPI SECTOR 110
10.4 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY METHOD OF SYNTHESIS 112
11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 118
11.1 INTRODUCTION 119
11.2 PEST ANALYSIS 122
11.2.1 POLITICAL FACTORS 122
11.2.2 ECONOMICAL FACTORS 122
11.2.3 SOCIAL FACTORS 123
11.2.4 TECHNOLOGICAL FACTORS 123
11.3 NORTH AMERICA 124
11.3.1 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 125
11.3.2 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 125
11.3.3 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 126
11.3.4 U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 128
11.3.5 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 128
11.3.6 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 130
11.4 EUROPE 131
11.4.1 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 132
11.4.2 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 132
11.4.3 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 133
11.4.4 U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 135
11.4.5 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 135
11.4.6 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 137
11.4.7 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 137
11.4.8 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 139
11.4.9 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 139
11.4.10 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 141
11.4.11 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 141
11.4.12 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 142
11.4.13 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 143
11.4.14 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 144
11.5 ASIA 145
11.5.1 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 145
11.5.2 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 145
11.5.3 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 146
11.5.4 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 147
11.5.5 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 147
11.5.6 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 149
11.5.7 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 149
11.5.8 SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 151
11.5.9 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 151
11.5.10 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 153
11.5.11 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 153
11.5.12 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 154
11.6 ROW 155
11.6.1 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 155
11.6.2 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 156
12 COMPETITIVE LANDSCAPE 157
12.1 COMPETITIVE SITUATION AND TRENDS 159
12.1.1 NEW PRODUCT LAUNCHES 159
12.1.2 MERGERS AND ACQUISITIONS 160
12.1.3 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES 161
12.1.4 EXPANSION 162
13 COMPANY PROFILES 163
(Overview, Financials, Products and Services, Strategy, and Developments)*
13.1 INTRODUCTION 163
13.2 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 164
13.3 DR. REDDY'S LABORATORIES LTD. 167
13.4 SUN PHARMACEUTICAL INDUSTRIES LTD. 170
13.5 AUROBINDO PHARMA LTD. 173
13.6 NOVARTIS INTERNATIONAL AG 176
13.7 ALBEMARLE CORPORATION 179
13.8 SIGMA-ALDRICH CORPORATION 182
13.9 MYLAN INC. 185
13.10 ALLERGAN PLC 188
13.11 BOEHRINGER INGELHEIM 190
*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.
14 APPENDIX 193
14.1 INSIGHTS FROM INDUSTRY EXPERTS 193
14.2 DISCUSSION GUIDE 194
14.3 OTHER DEVELOPMENTS, BY COMPANY, 2012-2015 198
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 206
14.5 AVAILABLE CUSTOMIZATIONS 206
14.6 RELATED REPORTS 207


LIST OF TABLES

TABLE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 58
TABLE 2 GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 60
TABLE 3 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 60
TABLE 4 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD BILLION) 61
TABLE 5 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 61
TABLE 6 GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE, 2013-2020 (USD BILLION) 62
TABLE 7 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 66
TABLE 8 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 67
TABLE 9 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 67
TABLE 10 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD BILLION) 68
TABLE 11 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 69
TABLE 12 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE, 2013-2020 (USD BILLION) 71
TABLE 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2013-2020 (USD BILLION) 75
TABLE 14 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY REGION, 2013-2020 (USD BILLION) 76
TABLE 15 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 77
TABLE 16 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 77
TABLE 17 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 78
TABLE 18 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY REGION, 2013-2020 (USD BILLION) 79
TABLE 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 80
TABLE 20 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 80
TABLE 21 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013-2020 (USD BILLION) 81
TABLE 22 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY TYPE, 2013-2020 (USD BILLION) 81
TABLE 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 85
TABLE 24 PATENTS EXPIRIES, 2015 86
TABLE 25 GLOBAL GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 88
TABLE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC AREA, 2013-2020 (USD BILLION) 90
TABLE 27 CANCER: ESTIMATED INCIDENCE, MORTALITY, AND PREVALENCE (2012) 91
TABLE 28 REGIONAL ESTIMATES FOR DIABETES (2013) 92
TABLE 29 U.S.: LEADING RESPIRATORY DRUGS, 2014 96
TABLE 30 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY REGION, 2013-2020 (USD BILLION) 98
TABLE 31 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 99
TABLE 32 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 99
TABLE 33 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD BILLION) 100
TABLE 34 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE, 2013-2020 (USD BILLION) 103
TABLE 35 GLOBAL GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 104
TABLE 36 NORTH AMERICA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 105
TABLE 37 EUROPE: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 105
TABLE 38 ASIA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 106
TABLE 39 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF MANUFACTURER, 2013-2020 (USD BILLION) 107
TABLE 40 GLOBAL CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 108
TABLE 41 NORTH AMERICA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 108
TABLE 42 EUROPE: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 109
TABLE 43 ASIA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 109
TABLE 44 GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 110
TABLE 45 NORTH AMERICA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 110
TABLE 46 EUROPE: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 111
TABLE 47 ASIA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 111
TABLE 48 GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION) 112
TABLE 49 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 112
TABLE 50 GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 113
TABLE 51 NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 113
TABLE 52 EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 114
TABLE 53 ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 114
TABLE 54 GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION) 115
TABLE 55 GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 115
TABLE 56 NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 116
TABLE 57 EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 116
TABLE 58 ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 117
TABLE 59 GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION) 117
TABLE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION,
2013-2020 (USD BILLION) 119
TABLE 61 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD BILLION) 120
TABLE 62 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION) 120
TABLE 63 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY,
2013-2020 (USD BILLION) 121
TABLE 64 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 126
TABLE 65 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 127
TABLE 66 U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 127
TABLE 67 U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 128
TABLE 68 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 129
TABLE 69 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 129
TABLE 70 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 130
TABLE 71 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 133
TABLE 72 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 134
TABLE 73 U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE, 2013-2020 (USD BILLION) 134
TABLE 74 U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 135
TABLE 75 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 136
TABLE 76 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 136
TABLE 77 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 137
TABLE 78 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 138
TABLE 79 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 138
TABLE 80 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 139
TABLE 81 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 140
TABLE 82 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 140
TABLE 83 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 141
TABLE 84 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 141
TABLE 85 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 142
TABLE 86 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 142
TABLE 87 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 143
TABLE 88 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 144
TABLE 89 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 144
TABLE 90 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 145
TABLE 91 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 146
TABLE 92 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 146
TABLE 93 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 147
TABLE 94 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 148
TABLE 95 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 148
TABLE 96 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 149
TABLE 97 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE, 2013-2020 (USD BILLION) 150
TABLE 98 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION) 150
TABLE 99 SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 151
TABLE 100 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 152
TABLE 101 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 152
TABLE 102 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 153
TABLE 103 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE,
2013-2020 (USD BILLION) 153
TABLE 104 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 154
TABLE 105 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION) 154
TABLE 106 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE,
BY PRODUCT, 2013-2020 (USD BILLION) 155
TABLE 107 ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION) 156
TABLE 108 NEW PRODUCT LAUNCHES 159
TABLE 109 MERGERS AND ACQUISITIONS 160
TABLE 110 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES 161
TABLE 111 EXPANSIONS 162
TABLE 112 SUN PHARMACEUTICALS INDUSTRIES LTD. 198
TABLE 113 TEVA PHARMACEUTICAL INDUSTRIES LIMITED 198
TABLE 114 DR. REDDY'S LABORATORIES 200
TABLE 115 AUROBINDO PHARMA 201
TABLE 116 NOVARTIS 201
TABLE 117 BOEHRINGER INGELHEIM 202
TABLE 118 ALBEMARLE CORPORATION 203
TABLE 119 SIGMA-ALDRICH 203
TABLE 120 MYLAN INC. 204
TABLE 121 ALLERGAN PLC. 204


LIST OF FIGURES

FIGURE 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 20
FIGURE 2 RESEARCH DESIGN 22
FIGURE 3 BOTTOM-UP APPROACH 27
FIGURE 4 TOP-DOWN APPROACH 28
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
FIGURE 6 API MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE API SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD 31
FIGURE 7 CAPTIVE MANUFACTURERS SEGMENT TO HOLD LARGEST MARKET SIZE IN 2015 32
FIGURE 8 SYNTHETIC APIS SEGMENT TO COMMAND LARGEST MARKET SIZE IN 2015 33
FIGURE 9 ONCOLOGY SEGMENT TO FORM LARGEST MARKET SHARE IN 2015 34
FIGURE 10 API MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE
IN 2015 35
FIGURE 11 HPAPI MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE HPAPI SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD 36
FIGURE 12 HPAPI MARKET, BY TYPE OF MANUFACTURER (2015 VS. 2020): THE CAPTIVE APIS SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD 37
FIGURE 13 HPAPI MARKET, BY MODE OF SYNTHESIS (2015 VS. 2020): SYNTHETIC APIS TO DOMINATE MARKET IN THE FORECAST PERIOD 38
FIGURE 14 HPAPI MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE
IN 2015 39
FIGURE 15 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES 40
FIGURE 16 THE ONCOLOGY SEGMENT TO ACCOUNT FOR THE LARGEST SIZE OF THE MARKET (2015-2020) 41
FIGURE 17 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015 42
FIGURE 18 MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020 43
FIGURE 19 THE ASIAN REGION TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD 44
FIGURE 20 GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES 45
FIGURE 21 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015 46
FIGURE 22 THE MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020 47
FIGURE 23 ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 48
FIGURE 24 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE 50
FIGURE 25 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION,
BY TYPE OF SYNTHESIS 51
FIGURE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION,
BY TYPE OF MANUFACTURER 51
FIGURE 27 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION,
BY THERAPEUTIC AREA 52
FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY REGION 53
FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
FIGURE 30 SYNTHETIC CHEMICAL ACTIVE PHARMACEUTICAL INGREDIENTS TO DOMINATE THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020) 58
FIGURE 31 NORTH AMERICA IS THE LARGEST SEGMENT OF THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD
(2015-2020) 59
FIGURE 32 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD (2015-2020) 62
FIGURE 33 RECOMBINANT PROTEINS TO DOMINATE THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015-2020) 65
FIGURE 34 NORTH AMERICA TO FORM THE LARGEST SEGMENT OF THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD
(2015-2020) 66
FIGURE 35 THE MERCHANT API MANUFACTURERS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE FORECAST PERIOD 74
FIGURE 36 CAPTIVE API MANUFACTURERS MARKET, BY REGION: ROW TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 76
FIGURE 37 MERCHANT API MANUFACTURERS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 79
FIGURE 38 GENERIC APIS TO WITNESS HIGHER GROWTH RATE 84
FIGURE 39 GENERIC ACTIVE PHARMACEUTICALS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD (2015-2020) 87
FIGURE 40 ONCOLOGY TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD 89
FIGURE 41 NORTH AMERICAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 124
FIGURE 42 EUROPEAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 131
FIGURE 43 KEY PLAYERS MAJORLY ADOPTED INORGANIC GROWTH STRATEGIES BETWEEN 2012 AND 2015 157
FIGURE 44 MARKET EVOLUTION FRAMEWORK -2014 WAS THE MOST ACTIVE YEAR DURING THE STUDIED PERIOD 158
FIGURE 45 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS BETWEEN 2012 AND 2015 159
FIGURE 46 GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 163
FIGURE 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 164
FIGURE 48 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT 167
FIGURE 49 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 170
FIGURE 50 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT 173
FIGURE 51 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT 176
FIGURE 52 ALBEMARLE CORPORATION: COMPANY SNAPSHOT 179
FIGURE 53 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT 182
FIGURE 54 MYLAN INC.: COMPANY SNAPSHOT 185
FIGURE 55 ALLERGAN PLC.: COMPANY SNAPSHOT 188
FIGURE 56 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT 190

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Poultry Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Poultry Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

This report on the poultry pharmaceuticals market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.